Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 May 23; 4(5):1344-1350.
-
Kwok T, Yeguvapalli S, Chitrala KN. Identification of Genes Crucial for Biological Processes in Breast Cancer Liver Metastasis Relapse. Int J Mol Sci. 2024 May 16; 25(10).
-
Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. Br J Cancer. 2024 Jun; 130(12):1943-1950.
-
Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Genome Med. 2024 02 12; 16(1):28.
-
Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
-
Wang Z, Katsaros D, Wang J, Biglio N, Hernandez BY, Fei P, Lu L, Risch H, Yu H. Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival. Sci Rep. 2023 11 03; 13(1):18962.
-
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024 Jan 01; 42(1):90-102.
-
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
-
Aflague TF, Hammond K, Delos Reyes B, Rios D, De Leon E, Leon Guerrero RT, Esquivel MK. Barriers, Facilitators, and Strategies for Developing a Culturally Informed Lifestyle Intervention for Native Hawaiian, CHamoru, and Filipino Breast Cancer Survivors: Mixed-Methods Findings from Focus Group Participants. Int J Environ Res Public Health. 2023 06 07; 20(12).
-
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034.